Evidence map›Paper›PMID 21403038›Full record

Trial reportArchives of internal medicine2011

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.

Ian H de Boer, Tessa C Rue, Patricia A Cleary, John M Lachin, Mark E Molitch, Michael W Steffes, Wanjie Sun, Bernard Zinman, John D Brunzell, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group and 6 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Archives of internal medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05378282 (Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics), which is not on this map. Cited by 173 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 5 pooled it
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05378282 completednot on this mapstarted 2021, after this paper: background citation

Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics

TypeobservationalSponsorHospital Juarez de MexicoRan2021 to 2023Enrolled40ConditionsType 2 Diabetes, Type 2 Diabetes With Renal Manifestations
3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 5 syntheses or guidelines pooled it, 344 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Glucose targets for preventing diabetic kidney disease and its progression.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. CNDP1 (CTG)Scientific reports · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Ian H de BoerKidney Research Institute and Division of Nephrology, University of Washington, Campus Box 359606, 325 Ninth Ave, Seattle, WA 98104, USA. deboer@u.washington.edu
Tessa C Rue
Patricia A Cleary
John M Lachin
Mark E Molitch
Michael W Steffes
Wanjie Sun
Bernard Zinman
John D Brunzell
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group
Neil H White
Ronald P Danis
Matthew D Davis
Dean Hainsworth
Larry D Hubbard
David M Nathan
University of Washington · US

Funding

INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCAUL1RR025014 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$51.5M
Institute for Translational Health Science (KL2)KL2RR025015 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$9.3M
Insulin Resistance in Chronic Kidney DiseaseR01DK087726 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2013
$1.9M
NCRR NIH HHS KL2 RR025015NCRR NIH HHS UL1 RR 025014NCRR NIH HHS UL1 RR025014NIDDK NIH HHS R01 DK087726
6 · The paper itself

Abstract

backgroundMicroalbuminuria is a common diagnosis in the clinical care of patients with type 1 diabetes mellitus. Long-term outcomes after the development of microalbuminuria are variable.

methodsWe quantified the incidence of and risk factors for long-term renal outcomes after the development of microalbuminuria in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The DCCT randomly assigned 1441 persons with type 1 diabetes to intensive or conventional diabetes therapy, and participants were subsequently followed up during the observational EDIC study. During the DCCT/EDIC study, 325 participants developed incident persistent microalbuminuria (albumin excretion rate, ≥30 mg/24 h at 2 consecutive study visits). We assessed their subsequent renal outcomes, including progression to macroalbuminuria (albumin excretion rate, ≥300 mg/24 h at 2 consecutive visits), impaired glomerular filtration rate (estimated glomerular filtration rate, <60 mL/min/1.73 m(2) at 2 consecutive study visits), end-stage renal disease, and regression to normoalbuminuria (albumin excretion rate, <30 mg/24 h at 2 consecutive visits).

resultsThe median follow-up period after persistent microalbuminuria diagnosis was 13 years (maximum, 23 years). Ten-year cumulative incidences of progression to macroalbuminuria, impaired glomerular filtration rate, end-stage renal disease, and regression to normoalbuminuria were 28%, 15%, 4%, and 40%, respectively. Albuminuria outcomes were more favorable with intensive diabetes therapy, lower glycated hemoglobin level, absence of retinopathy, female sex, lower blood pressure, and lower concentrations of low-density lipoprotein cholesterol and triglycerides. Lower glycated hemoglobin level, absence of retinopathy, and lower blood pressure were also associated with decreased risk of impaired glomerular filtration rate.

conclusionsAfter the development of persistent microalbuminuria, progression and regression of kidney disease each commonly occur. Intensive glycemic control, lower blood pressure, and a more favorable lipid profile are associated with improved outcomes.

Indexed as

AdultAge of OnsetAlbuminuriaBlood PressureCholesterol, LDLChronic DiseaseDiabetes Mellitus, Type 1Diabetic RetinopathyDisease ProgressionFemaleFollow-Up StudiesGlomerular Filtration RateHemoglobinsHumansHypoglycemic AgentsInsulinCholesterol, LDLHemoglobinsHypoglycemic AgentsInsulinTriglycerides

Identifiers

PMID21403038
PMCPMC3085024
OpenAlexW1907964358

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.